Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: Results of the 2005 Spring US National Psoriasis Foundation Survey

American Journal of Clinical Dermatology

Volumn 9, Issue 2, 2008, Pages 111-117

  Ciocon, David H ^a   Horn, Elizabeth J ^b   Kimball, Alexa B ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b National Psoriasis Foundation   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Psoriasis, general; Psoriatic arthritis, general; Quality of life

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PSORALEN; TACROLIMUS; TAZAROTENE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; STATISTICS AS TOPIC; UNITED STATES;

EID: 39549104281     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809020-00004     Document Type: Article

References (18)

1. Mease PJ, Menter AM. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2005; 54: 685-704
2. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49 Suppl.: S57-61
3. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effects of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-8
4. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-8
5. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137 (3): 280-4
6. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6 (6): 383-92
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
8. Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004; 50 (1): 24-35
9. O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996; 313: 919-21
10. Kay L, Myers A, Walker D. Effects of inflammatory arthritis on quality of life in patients with psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1655
11. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80 (6): 430-4
12. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82 (2): 108-13
13. Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002; 3: 171-9
14. Koo J, Kozma CM, Menter A, et al. Development of the 12 item Psoriasis Quality of Life Questionnaire (PQOL) [poster no. 606]. 61st annual meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco (CA)
15. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281-5
16. Nijsten T, Rolstad T, Feldman SR, et al. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005; 141 (1): 19-26
17. Symmons DP, Lunt M, Watkins G, et al. Developing classification criteria for peripheral joint psoriatic arthritis: step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". J Rheumatol 2006; 33 (3): 552-7
18. Stamm TA, Nell V, Mathis M, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007; 57 (3): 487-94